AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Smith+Nephew to Announce Q2 and H1 2025 Results on August 5
ByAinvest
Wednesday, Jul 23, 2025 4:36 am ET1min read
Smith+Nephew to announce Q2 and H1 2025 results on August 5. The company, a global medical technology firm, operates in three main business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The results will be followed by a conference call for financial analysts, highlighting the company's commitment to transparency and engagement with stakeholders.
Smith+Nephew, a global medical technology firm, is set to release its second quarter (Q2) and first half (H1) 2025 financial results on Tuesday, August 5, 2025. The company, headquartered in London, specializes in orthopedics, sports medicine, ENT (ear, nose, and throat), and advanced wound management. The results will cover the period ended June 28, 2025 [1].Following the announcement, Smith+Nephew will host a conference call for financial analysts at 8:30am BST (2:00am EDT) on the same day. This event underscores the company's commitment to transparency and engagement with stakeholders [2].
Smith+Nephew operates in approximately 100 countries, with a workforce of 17,000 employees. In 2024, the company reported annual sales of $5.8 billion, focusing on medical technology for the repair, regeneration, and replacement of soft and hard tissue [1].
The company is listed on both the London Stock Exchange (LSE:SN) and the New York Stock Exchange (NYSE:SNN). Smith+Nephew is also a constituent of the FTSE 100 index [1].
References:
[1] https://za.investing.com/news/company-news/smithnephew-to-announce-q2-and-h1-2025-results-on-august-5-93CH-3796504
[2] https://www.investing.com/news/company-news/smithnephew-to-announce-q2-and-h1-2025-results-on-august-5-93CH-4143456
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet